Blog Posts
Q&A with PULSE Partner BioNJ on the Local Impact of Life Sciences M&A
PULSE recently sat down for a conversation on life sciences M&A with Debbie Hart, President and CEO at BioNJ, the life sciences trade association for New Jersey.
By the Numbers: Citeline’s R&D Annual Review Underscores Importance of Life Sciences M&A
Findings from Citeline’s latest report, Pharma R&D Annual Review 2026, highlight the continued U.S. leadership in the life sciences ecosystem.
ICYMI: ITIF Report Underscores the Importance of Balanced Antitrust Enforcement
A recent report from the Information Technology and Innovation Foundation (ITIF), “Antitrust Undone: How Competition Enforcers Are Undermining Competition,” highlights the risks of unnecessarily aggressive antitrust enforcement in innovative industries. The report cautions that such policies could, “adversely impact U.S. global competitiveness and innovative dynamism.”
Innovations Advanced by M&A: A New Treatment for Hyperkalemia
AstraZeneca’s acquisition of ZS Pharma helped bring a treatment for hyperkalemia to patients globally.
M&A Is Essential to Sustaining Life Sciences Momentum in 2026
Life sciences M&A activity gained momentum in late 2025, and that acceleration is expected to continue in 2026. This positive trend is vitally important for the many treatments and cures that depend on these partnerships to reach patients.
ICYMI: Congressional Briefing Spotlights Value of Life Sciences M&A
New research presented at a Congressional staff briefing highlighted the strong, positive relationship between pharmaceutical mergers and acquisitions (M&A) and the launches of new drugs for patients. Research Finds that Pharmaceutical M&A Drives New, Novel...
2H 2025 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences.
Rebounding Life Sciences M&A Signals Strength for Innovation
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem.
Innovations Advanced by M&A: A New Medicine Treating Anemia for Patients with Myelofibrosis
GlaxoSmithKline (GSK)’s 2022 acquisition of Sierra Oncology combined Sierra’s specialization in developing targeting therapies for rare blood cancers with GSK’s global scale, regulatory experience and commercialization capabilities — leading to approval of the only first-line medicine to treat myelofibrosis patients who have anemia.
M&A Powers Innovation to Fill Unmet Medical Needs
To address the unmet medical needs of those with rare diseases requires groundbreaking science in diseases that are not well understood, and this high degree of complexity often means that mergers and acquisitions (M&A) are critically important for companies to be successful in bringing new treatments to patients.